Accessibility Menu
Werewolf Therapeutics logo

Werewolf Therapeutics

(NASDAQ) HOWL

Current Price$0.36
Market Cap$17.88MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-98%
5 Year-98%
1 Year-74%
1 Month+7%
Werewolf Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 0.372026-07-17
Werewolf Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-8.68%USD 0.402026-07-10
1 month+6.98%USD 0.342026-06-17
3 month-61.09%USD 0.952026-04-17
Year to date-41.91%USD 0.632025-12-31
1 year-73.71%USD 1.402025-07-17
3 year-88.43%USD 3.182023-07-18
5 year-97.68%USD 15.892021-07-16
Since inception-97.71%USD 16.102021-04-30

Werewolf Therapeutics Financials at a Glance

Market Cap

$17.88MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$56.27M

EPS (TTM)

-$1.21

P/E Ratio

-0.30

Dividend

$0.00

Beta (Volatility)

1.52 (High)

Price

$0.36

Volume

340,135.475

Open

$0.37

Previous Close

$0.37

Daily Range

$0.34 - $0.38

52-Week Range

$0.27 - $2.38

Estimated Earnings Date

Aug 13, 2026

HOWL News

Foolcom-Featured.png

Werewolf Reports No Revenue in Fiscal Q2

Motley Fool Markets TeamAug 14, 2025

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Werewolf Therapeutics

Werewolf Therapeutics, Inc. is a biotechnology firm focused on creating innovative therapeutics aimed at stimulating the body's immune system to combat cancer and immune-mediated conditions. The company uses its proprietary PREDATOR platform to develop conditionally activated immune molecules called INDUKINEs. These are designed to activate specifically within the tumor microenvironment, aiming to address limitations of traditional immune therapies.

Products and Services

WTX-124: A conditionally activated IL-2 INDUKINE molecule for treating solid tumors.

WTX-330: A conditionally activated IL-12 INDUKINE molecule aimed at cancer and lymphoma treatment.

WTX-712: An IL-21 INDUKINE molecule in preclinical development for antitumor T cell response.

WTX-518: An IL-18 INDUKINE molecule designed for robust immune activation in tumors.

WTX-921: An IL-10 INDUKINE molecule targeting inflammatory diseases like inflammatory bowel disease (IBD).

What Makes Werewolf Therapeutics, Inc. Special

Werewolf Therapeutics, Inc. distinguishes itself through its PREDATOR platform, which enables the development of conditionally activated molecules that are systemically delivered but only activated in the tumor microenvironment. This approach aims to optimize the potency and minimize the systemic toxicity associated with traditional immune therapies. By focusing on this innovative method, the company aims to overcome existing challenges in cancer treatment.

Five Things You Need to Know

Werewolf Therapeutics is conducting clinical trials for its lead candidates, WTX-124 and WTX-330, in various tumor types.

The PREDATOR platform integrates multiple engineered components into a single molecule for targeted activation.

In November 2023, the company reported initial clinical data establishing proof of mechanism for WTX-124.

Partnership with Jazz Pharmaceuticals has granted the rights to develop and commercialize JZP898, previously WTX-613.

Werewolf is expanding its platform to address a wider array of diseases, including autoimmune and inflammatory disorders.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

14

CEO

Dan Hicklin, PhD

Website

www.werewolftx.com

Headquarters

Watertown, MA 02138, US

HOWL Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-208.23%

Return on Capital

-177.21%

Return on Assets

-96.97%

Earnings Yield

-3.33%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$17.88MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

48.60M

Volume

340.14K

Avg. Volume

697.87K

Financials (TTM)

Gross Profit

-$804.00K

Operating Income

-$51.65M

EBITDA

-$49.28M

Operating Cash Flow

-$51.94M

Capital Expenditure

$0.00

Free Cash Flow

-$51.94M

Cash & ST Invst.

$46.45M

Total Debt

$37.65M

Werewolf Therapeutics Performance Analysis

Werewolf Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 16,401,000N/A
20232023-12-31USD 19,943,00021.6%
20242024-12-31USD 1,885,000-90.5%
20252025-12-31USD 0N/A
Werewolf Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Werewolf Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1.86-74.8%
20232023-12-31USD -1.05-43.8%
20242024-12-31USD -1.6355.8%
20252025-12-31USD -1.33-18.8%
Werewolf Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-3010.0%
Q42025-12-3152.8%
Q12026-03-31-64.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$398.00K

+6.6%

Gross Margin

0.00%

N/A

Market Cap

$17.88MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.28M

N/A

Employees

14

N/A

Net Income

-$13.53M

+25.2%

EBITDA

-$11.77M

+28.3%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$46.45M

-49.5%

Total Debt

$37.65M

+1.7%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$7.22M

-79.7%

Short Term Debt

$30.44M

+2055.5%

Return on Assets

-96.97%

N/A

Return on Invested Capital

-2.65%

N/A

Free Cash Flow

-$10.60M

+44.1%

Operating Cash Flow

-$10.60M

+44.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
LITSLite Strategy, Inc.
$0.99+1.69%
IOBTIO Biotech, Inc.
$0.01-27.59%
INMBINmune Bio, Inc.
$1.90-8.21%
OTLKOutlook Therapeutics, Inc.
$1.39-4.79%

Trending Stocks

Symbol / CompanyPricePrice Chg
ONDSOndas
$6.53-0.02%
AALAmerican Airlines Group
$14.98-0.04%
NOKNokia
$10.12-0.03%
NUNu Holdings
$13.59-0.01%

Questions About HOWL

What is the current price of Werewolf Therapeutics?

Werewolf Therapeutics is trading at $0.37 per share.

What is the 52-week range for Werewolf Therapeutics?

Over the past 52 weeks, Werewolf Therapeutics has traded between $0.27 and $2.38.

How much debt does Werewolf Therapeutics have?

As of the most recent reporting period, Werewolf Therapeutics reported total debt of $37.65M.

How much cash does Werewolf Therapeutics have on hand?

Werewolf Therapeutics reported $46.45M in cash and cash equivalents in its most recent financial results.

What is Werewolf Therapeutics’s dividend yield?

Werewolf Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services